Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates The following represents disclosure information provided by authors of this ...
NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...
Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment ...
Researchers engineered a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.
The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.
Introduction Skin rash is the most common adverse effect in patients with cancer receiving epidermal growth factor receptor inhibitors (EGFRIs), which can impair quality of life and lead to treatment ...
In a new study, clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) have demonstrated the use of exosomes to successfully target squamous cell cancer tumours that are ...
Nearly 40 years ago, researchers identified the epidermal growth factor (EGF) domain as a key component in mussel adhesive proteins. Since then, similar adhesive proteins have been discovered in a ...
The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results